The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer
Citation:KJ O'Byrne, The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer, Cancers, 3, 1, 2011, 1426-1453
The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer.pdf (Published (publisher's copy) - Peer Reviewed) 308.0Kb
Non-small cell lung cancer (NSCLC) is the most common cause of cancer related death in the world. Cisplatin and carboplatin are the most commonly used cytotoxic chemotherapeutic agents to treat the disease. These agents, usually combined with drugs such as gemcitabine or pemetrexed, induce objective tumor responses in only 20?30% of patients. Aberrant epigenetic regulation of gene expression is a frequent event in NSCLC. In this article we review the emerging evidence that epigenetics and the cellular machinery involved with this type of regulation may be key elements in the development of cisplatin resistance in NSCLC.
Type of material:Journal Article
Availability:Full text available